219 related articles for article (PubMed ID: 18371162)
1. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
2. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Martinowitz U; Livnat T; Zivelin A; Kenet G
Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
[TBL] [Abstract][Full Text] [Related]
3. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Klintman J; Astermark J; Berntorp E
Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
5. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
8. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
Klintman J; Berntorp E; Astermark J;
Haemophilia; 2010 Jan; 16(1):e210-5. PubMed ID: 19878339
[TBL] [Abstract][Full Text] [Related]
10. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
11. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
[TBL] [Abstract][Full Text] [Related]
12. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
13. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
Livnat T; Martinowitz U; Zivelin A; Rima D; Kenet G
Thromb Haemost; 2011 Apr; 105(4):688-95. PubMed ID: 21225093
[TBL] [Abstract][Full Text] [Related]
14. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.
Parmar N; Berry LR; Paredes N; Chan AK
Clin Lab; 2005; 51(3-4):157-66. PubMed ID: 15819171
[TBL] [Abstract][Full Text] [Related]
15. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
18. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C
Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902
[TBL] [Abstract][Full Text] [Related]
19. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
20. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]